Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GPC3-CART cells
- Development stage
- Phase 2
- Lead developer
- Shanghai Genechem Co.
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intratumor Injection
01
Overview
GPC3-CART cells represent a second-generation Chimeric Antigen Receptor T-cell (CAR-T) therapy. These engineered T cells are designed to specifically target Glypican-3 (GPC3), a protein often overexpressed in certain cancers. The CAR construct incorporates 4-1BB as a co-stimulatory domain, aiming to enhance T-cell proliferation, survival, and anti-tumor activity. The therapy is being investigated for intratumoral injection to concentrate T cells at the tumor site, potentially improving efficacy and reducing systemic side effects. Shanghai GeneChem Co., Ltd. is the lead sponsor of its development.
- Other names
- Glypican-3-targeted CAR-T cellsGlypican3-targeted CAR-T cellsGlypican 3-targeted CAR-T cells
02
Targets
GPC3 (Glypican-3)
Beyond the preview
Go deeper on GPC3-CART cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GPC3-CART cells.